The DOL House:

Influence in pharma is changing. No longer do we have to choose between KOLs or DOLs (Digital Opinion Leaders). DOLs, already noted for their digital reach, accessibility and wider influence, are set to rise as a new generation of Key Opinion Leaders (KOLs), nurtured and empowered by pharma.

This transition is more than just an exchange of influence; it signifies a more profound and intricate evolution within the industry. This mini-report offers an insightful exploration of this transformative process. We unravel the complexities of strengthening DOLs to become KOLs, arming them with deep-rooted expertise and respectability that goes beyond digital prowess.

Discover how your organization can navigate this shift, aligning your objectives with the aspirations and capabilities of these emerging influencers. Master the principles of building a sustainable model of influence, one that synergizes the contemporary acumen of DOLs with the traditional wisdom of KOLs. This is an invitation to comprehend, embrace a more democratic industry that nonetheless reinforces your key aims and objectives.

Paul Simms
Chief Executive, Impatient Health